IQV Quote, Financials, Valuation and Earnings

CVS Health has a net margin of 11.04% compared to IQVIA Holdings's net margin of 1.68%. IQVIA Holdings's return on equity of 21.32% beat CVS Health's return on equity of 6.12%.

IQVIA Holdings has a consensus price target of $245.68, signalling upside risk potential of 45.83%. On the other hand CVS Health has an analysts' consensus of $72.26 which suggests that it could grow by 7.03%. Given that IQVIA Holdings has higher upside potential than CVS Health, analysts believe IQVIA Holdings is more attractive than CVS Health.

IQVIA Holdings has a beta of 1.459, which suggesting that the stock is 45.883% more volatile than S&P 500. In comparison CVS Health has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.622%.

IQVIA Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 3.94% to investors and pays a quarterly dividend of $0.67 per share. IQVIA Holdings pays -- of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IQVIA Holdings quarterly revenues are $4B, which are smaller than CVS Health quarterly revenues of $97.7B. IQVIA Holdings's net income of $437M is lower than CVS Health's net income of $1.6B. Notably, IQVIA Holdings's price-to-earnings ratio is 22.36x while CVS Health's PE ratio is 18.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IQVIA Holdings is 2.00x versus 0.23x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

First Physicians Capital Group has a net margin of 11.04% compared to IQVIA Holdings's net margin of --. IQVIA Holdings's return on equity of 21.32% beat First Physicians Capital Group's return on equity of --.

IQVIA Holdings has a consensus price target of $245.68, signalling upside risk potential of 45.83%. On the other hand First Physicians Capital Group has an analysts' consensus of -- which suggests that it could fall by --. Given that IQVIA Holdings has higher upside potential than First Physicians Capital Group, analysts believe IQVIA Holdings is more attractive than First Physicians Capital Group.

IQVIA Holdings has a beta of 1.459, which suggesting that the stock is 45.883% more volatile than S&P 500. In comparison First Physicians Capital Group has a beta of -12.023, suggesting its less volatile than the S&P 500 by 1302.307%.

IQVIA Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IQVIA Holdings pays -- of its earnings as a dividend. First Physicians Capital Group pays out -- of its earnings as a dividend.

IQVIA Holdings quarterly revenues are $4B, which are larger than First Physicians Capital Group quarterly revenues of --. IQVIA Holdings's net income of $437M is higher than First Physicians Capital Group's net income of --. Notably, IQVIA Holdings's price-to-earnings ratio is 22.36x while First Physicians Capital Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IQVIA Holdings is 2.00x versus 1.40x for First Physicians Capital Group. Usually stocks with elevated PS ratios are considered overvalued.

UNIVEC has a net margin of 11.04% compared to IQVIA Holdings's net margin of --. IQVIA Holdings's return on equity of 21.32% beat UNIVEC's return on equity of --.

IQVIA Holdings has a consensus price target of $245.68, signalling upside risk potential of 45.83%. On the other hand UNIVEC has an analysts' consensus of -- which suggests that it could fall by --. Given that IQVIA Holdings has higher upside potential than UNIVEC, analysts believe IQVIA Holdings is more attractive than UNIVEC.

IQVIA Holdings has a beta of 1.459, which suggesting that the stock is 45.883% more volatile than S&P 500. In comparison UNIVEC has a beta of 0.149, suggesting its less volatile than the S&P 500 by 85.124%.

IQVIA Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UNIVEC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IQVIA Holdings pays -- of its earnings as a dividend. UNIVEC pays out -- of its earnings as a dividend.

IQVIA Holdings quarterly revenues are $4B, which are larger than UNIVEC quarterly revenues of --. IQVIA Holdings's net income of $437M is higher than UNIVEC's net income of --. Notably, IQVIA Holdings's price-to-earnings ratio is 22.36x while UNIVEC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IQVIA Holdings is 2.00x versus -- for UNIVEC. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 11.04% compared to IQVIA Holdings's net margin of -55.94%. IQVIA Holdings's return on equity of 21.32% beat SCWorx's return on equity of -80.46%.

IQVIA Holdings has a consensus price target of $245.68, signalling upside risk potential of 45.83%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that IQVIA Holdings has higher upside potential than SCWorx, analysts believe IQVIA Holdings is more attractive than SCWorx.

IQVIA Holdings has a beta of 1.459, which suggesting that the stock is 45.883% more volatile than S&P 500. In comparison SCWorx has a beta of 3.403, suggesting its more volatile than the S&P 500 by 240.336%.

IQVIA Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IQVIA Holdings pays -- of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.

IQVIA Holdings quarterly revenues are $4B, which are larger than SCWorx quarterly revenues of $759.7K. IQVIA Holdings's net income of $437M is higher than SCWorx's net income of -$425K. Notably, IQVIA Holdings's price-to-earnings ratio is 22.36x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IQVIA Holdings is 2.00x versus 0.32x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.